Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2015-11-02
Original SEC Filing: Click here

---

Webplus: SVA/20151102/6-K/2_EX-99.1/000.htm SEC Original: v423311_ex99-1.htm
Sinovac Receives Clinical Trial Approval for Varicella Vaccine Candidate BEIJING, Oct. 26, 2015 /PRNewswire/ — Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that one of its subsidiaries, Sinovac Dalian, has received approval to begin human clinical trials on its varicella vaccine candidate. The clinical trial application for the varicella vaccine was officially accepted

---

---

Webplus: SVA/20151102/6-K/1/000.htm SEC Original: v423311_6k.htm

---

Company Information:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2015-11-02CIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
39 SHANGDI XI ROAD
BEIJING 100085